BGI Genomics 過去の業績

SZSE:300676 収益、費用、利益 ( )CNY Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 24	4,032	-102	1,497	533
30 Jun 24	4,149	61	1,490	510
31 Mar 24	4,216	64	1,508	508
31 Dec 23	4,350	93	1,507	523
30 Sep 23	5,679	126	1,832	522
30 Jun 23	5,964	247	1,969	527
31 Mar 23	6,578	514	2,145	517
01 Jan 23	7,053	803	2,183	526
30 Sep 22	6,132	794	1,983	513
30 Jun 22	6,281	981	1,805	522
31 Mar 22	6,633	1,267	1,776	513
01 Jan 22	6,766	1,462	1,742	475
30 Sep 21	6,797	798	2,028	709
30 Jun 21	7,936	1,523	2,019	656
31 Mar 21	9,169	2,474	1,857	622
31 Dec 20	8,397	2,089	1,771	611
30 Sep 20	7,480	2,712	1,160	335
30 Jun 20	5,617	1,730	1,085	332
31 Mar 20	3,009	318	976	318
31 Dec 19	2,800	276	927	306
30 Sep 19	2,795	337	1,004	303
30 Jun 19	2,687	377	878	283
31 Mar 19	2,603	384	836	267
31 Dec 18	2,536	387	792	237
30 Sep 18	2,463	406	696	214
30 Jun 18	2,348	415	602	255
31 Mar 18	2,224	404	602	205
31 Dec 17	2,096	398	611	163
30 Sep 17	1,901	388	630	111
30 Jun 17	1,833	375	747	0
31 Mar 17	1,796	352	852	0
31 Dec 16	1,711	333	725	0
30 Jun 16	1,520	336	555	0
31 Mar 16	1,339	299	357	0
31 Dec 15	1,319	262	460	0
31 Dec 14	1,132	28	452	0
31 Dec 13	1,047	136	358	0

質の高い収益: 300676は現在利益が出ていません。

利益率の向上: 300676は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 300676は利益が出ておらず、過去 5 年間で損失は年間32%の割合で増加しています。

成長の加速: 300676の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: 300676は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 0.08% ) と比較することは困難です。

株主資本利益率

高いROE: 300676は現在利益が出ていないため、自己資本利益率 ( -1.01% ) はマイナスです。

BGI Genomics 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Third quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.045 profit in 3Q 2023)

BGI Genomics Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Second quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.027 in 2Q 2023)

BGI Genomics Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.091 in 1Q 2023)

BGI Genomics' (SZSE:300676) Conservative Accounting Might Explain Soft Earnings

Recent updates

Third quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.045 profit in 3Q 2023)

Is BGI Genomics (SZSE:300676) Using Too Much Debt?

BGI Genomics Co., Ltd. (SZSE:300676) Held Back By Insufficient Growth Even After Shares Climb 31%

BGI Genomics Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Second quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.027 in 2Q 2023)

High number of new directors

Is BGI Genomics (SZSE:300676) A Risky Investment?

BGI Genomics Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

BGI Genomics Co., Ltd. Announces Final Cash Dividend Plan on A Shares for the Year 2023, Payable on 4 July 2024

BGI Genomics Co., Ltd. Announces Board Appointments

Why Investors Shouldn't Be Surprised By BGI Genomics Co., Ltd.'s (SZSE:300676) Low P/S

Bgi Genomics Co., Ltd. Approves Cash Dividend for 2023

First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.091 in 1Q 2023)

BGI Genomics' (SZSE:300676) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings released: EPS: CN¥0.23 (vs CN¥1.96 in FY 2022)

BGI Genomics Co., Ltd., Annual General Meeting, May 09, 2024

BGI Genomics Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Here's Why BGI Genomics (SZSE:300676) Can Manage Its Debt Responsibly

Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥1.96 in FY 2022)

BGI Genomics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 13, 2024

Third quarter 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.35 in 3Q 2022)

New major risk - Dividend sustainability

Second quarter 2023 earnings released: EPS: CN¥0.027 (vs CN¥0.68 in 2Q 2022)

BGI Genomics Co., Ltd. to Report First Half, 2023 Results on Aug 12, 2023

Bgi Genomics Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 7 June 2023

First quarter 2023 earnings released: EPS: CN¥0.091 (vs CN¥0.81 in 1Q 2022)

Investor sentiment improves as stock rises 30%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.80 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥20.98 (vs CN¥1.37 in 2Q 2021)

BGI Genomics Announces Final Profit Distribution for 2021 payable on 06 July 2022

BGI Genomics Co., Ltd. Approves Cash Dividend for the Year 2021

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

BGI Genomics Co., Ltd. Announces Final Cash Dividend Proposal for 2021

Investor sentiment improved over the past week

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2021 earnings released: EPS CN¥1.37 (vs CN¥3.79 in 2Q 2020)

Chairman of Scientific Advisory Board Tadataka Yamada has left the company

Chairman of Scientific Advisory Board Tadataka Yamada has left the company

Investor sentiment improved over the past week

BGI Genomics Co., Ltd. (SZSE:300676) completed the acquisition of remaining 1% stake in Beijing BGI Medical Laboratory Co., Ltd. from Beijing BGI Research Centre Co., Ltd.

Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China

BGI Genomics Co., Ltd. Approves Cash Dividend for 2020

BGI Genomics Co., Ltd. (SZSE:300676) agreed to acquire the remaining 1% stake in Beijing BGI Medical Laboratory Co., Ltd. from Beijing BGI Research Centre Co., Ltd. for CNY 2.37 million.

BGI Genomics Co., Ltd. Announces Final Cash Dividend Proposal for 2020

First quarter 2021 earnings released: EPS CN¥1.29 (vs CN¥0.35 in 1Q 2020)

New 90-day low: CN¥125

Full year 2020 earnings released: EPS CN¥5.23 (vs CN¥0.69 in FY 2019)

Revenue and earnings miss expectations

Investor sentiment deteriorated over the past week

New 90-day high: CN¥166

Investor sentiment improved over the past week

New 90-day low: CN¥127

New 90-day low: CN¥133

Third quarter earnings released

New 90-day low: CN¥133

First half earnings released

BGI Genomics Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

BGI Genomics Co., Ltd. announced that it expects to receive CNY 2.0119372 billion in funding

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06